Kyowa Kirin announces positive interim data for lymphoma treatment

Real-world studies show effectiveness of mogamulizumab in routine practice

Kyowa Kirin International (KKI) has announced positive interim findings from three real-world studies on mogamulizumab (Poteligeo) for cutaneous T-cell lymphoma (CTCL).

The data will be presented at the European Organisation for Research and Treatment of Cancer’s Cutaneous Lymphoma Tumour Group (EORTC-CLTG) meeting in Lausanne, Switzerland, from 9th–11th October 2024.

The studies, involving participants from Europe, the US, and the UAE, aim to gather real-world evidence on mogamulizumab, a first-in-class humanised monoclonal antibody therapy.

Approved in Europe and the UAE for treating mycosis fungoides (MF) or Sézary Syndrome (SS) in adults who have had at least one prior systemic therapy, mogamulizumab is also approved in the US and Switzerland for relapsed or refractory cases.

Professor Emmanuella Guenova, chief physician of dermatology and venereology at Lausanne University Hospital, said, “For most patients, treatment of CTCL aims to prolong time to disease progression, reduce the burden of disease and preserve or enhance quality of life. The real-world evidence being established by Kyowa Kirin is invaluable information for physicians.”

The second interim analyses from these studies include MINT (Germany) and MIBERIC (Spain and Portugal), which show the effectiveness and tolerability of mogamulizumab in real-world settings, aligning with global clinical trial data. No new safety signals were observed.

PROSPER (US, UAE, Spain, Italy, Netherlands, UK) is an ongoing study assessing the impact of mogamulizumab on patients with MF and SS, focusing on symptoms, health-related quality of life, and effects on primary care partners.

Patients reported improvements in skin symptoms, sleep, and body temperature within four weeks, and in fatigue and quality of life within 24 weeks.

Dr Nicholas Kronfeld, Senior Vice President, Head of Medical Affairs at KKI, commented, “The studies being presented at EORTC-CLTG build on our presentations at last year’s annual meeting and reinforce our commitment to providing the community with a wide breadth of real-world data to inform clinical decision-making and hopefully improve patient outcomes.”

Kyowa Kirin will present three accepted abstracts at EORTC-CLTG 2024, demonstrating their ongoing commitment to advancing CTCL treatment.